DR. HEINZ-JOSEF LENZ, M.D.
Osteopathic Medicine in Los Angeles, CA
License number
California A63854
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
California A63854
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1441 Eastlake Ave., Los Angeles, CA 90033
Phone
(323) 865-3105
(323) 865-0061 (Fax)
(323) 442-5100
(323) 865-0061 (Fax)
(323) 442-5100
Organization information
See more information about HEINZ-JOSEF LENZ at bizstanding.comUsc Internal Medicine - Heinz-Josef Lenz MD
1441 Eastlake Ave #34, Los Angeles, CA 90089
Categories:
Physicians & Surgeons
Phone:
(323) 442-5100 (Phone)
Professional information
See more information about HEINZ-JOSEF LENZ at trustoria.com
Polymorphisms In Angiogenesis Pathway Genes Associated With Tumor Recurrence In Surgery Treated Cancer Patients
Polymorphisms In Angiogenesis Pathway Genes Associated With Tumor Recurrence In Surgery Treated Cancer Patients
US Patent:
2012010, May 3, 2012
Filed:
Apr 23, 2010
Appl. No.:
13/265837
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
International Classification:
C12Q 1/68, C40B 40/06, C40B 20/00
US Classification:
506 2, 435 611, 506 16
Abstract:
This invention provides compositions and methods for determining the likely tumor recurrence of cancer patients after surgical resection. Said methods are based on determining the patient's genotype for the polymorphisms PAR-1-506 ins/del C and/or EGF+61A>G.
Heinz-Josef J Lenz, Los Angeles CA
Heinz-Josef J Lenz, Los Angeles CA
Specialties:
Oncologist
Address:
1355 San Pablo St, Los Angeles, CA 90033
1303 N Mission Rd, Los Angeles, CA 90033
1441 Eastlake Ave, Los Angeles, CA 90089
1303 N Mission Rd, Los Angeles, CA 90033
1441 Eastlake Ave, Los Angeles, CA 90089
Polymorphism In K-Ras 3' Untranslated Region Associated With Clinical Outcomes Of Cancer Treatments Independent Of K-Ras Mutation Status
Polymorphism In K-Ras 3' Untranslated Region Associated With Clinical Outcomes Of Cancer Treatments Independent Of K-Ras Mutation Status
US Patent:
2012010, May 3, 2012
Filed:
Oct 20, 2011
Appl. No.:
13/278101
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
International Classification:
A61K 39/395, A61P 35/00, A61K 31/4375, C12Q 1/68, C40B 20/00
US Classification:
4241331, 435 611, 506 2, 514283
Abstract:
The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with anti-EGFR therapy, topoisomerase inhibitor therapy or anti-EGFR therapy/topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.
Ercc-1 Gene Expression Predicts Chemotherapy Outcome
Ercc-1 Gene Expression Predicts Chemotherapy Outcome
US Patent:
2011010, May 5, 2011
Filed:
May 14, 2009
Appl. No.:
12/992583
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
International Classification:
A61K 31/519, C12Q 1/68, G01N 33/574, C40B 30/04, A61P 35/00
US Classification:
51425505, 435 6, 435 723, 506 9
Abstract:
The invention provides compositions and methods for determining the likelihood of successful treatment with a first line FOLFOX chemotherapy regimen or in further combination with PTK/ZK. The methods comprise determining the gene expression levels of a gene of interest and correlating the high or low expression to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.
Genetic Markers For Predicting Responsiveness To Combination Therapy
Genetic Markers For Predicting Responsiveness To Combination Therapy
US Patent:
8357369, Jan 22, 2013
Filed:
Sep 29, 2011
Appl. No.:
13/249148
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A61K 39/395
US Classification:
4241411, 435 614, 435 723
Abstract:
The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy.
Thymidylate Synthase Haplotype Is Associated With Tumor Recurrence In Stage Ii And Stage Iii Colon Cancer Patients
Thymidylate Synthase Haplotype Is Associated With Tumor Recurrence In Stage Ii And Stage Iii Colon Cancer Patients
US Patent:
2011016, Jun 30, 2011
Filed:
Jun 10, 2008
Appl. No.:
12/996676
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
International Classification:
C12Q 1/68, A61K 31/513, A61K 31/519, A61P 35/00
US Classification:
514249, 435 611, 514274
Abstract:
The invention provides compositions and methods for determining the likelihood of tumor recurrence following treatment with 5-FU based adjuvant therapy for Stage II or Stage III colon cancer patients. After determining if a patient is less likely to experience tumor recurrence once treated, the invention also provides methods for treating these patients.
Polymorphisms For Predicting Disease And Treatment Outcome
Polymorphisms For Predicting Disease And Treatment Outcome
US Patent:
2013019, Aug 1, 2013
Filed:
Feb 1, 2013
Appl. No.:
13/757610
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
Jan Stoehlmacher - Dresden, DE
David Jong-Han Park - Rowland Heights CA, US
Jan Stoehlmacher - Dresden, DE
David Jong-Han Park - Rowland Heights CA, US
International Classification:
C12Q 1/68, A61K 31/635
US Classification:
514158, 435 611
Abstract:
The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.
Polymorphisms In Voltage-Gated Sodium Channel Alpha 1-Subunit As Markers For Therapy Selection
Polymorphisms In Voltage-Gated Sodium Channel Alpha 1-Subunit As Markers For Therapy Selection
US Patent:
8318426, Nov 27, 2012
Filed:
Mar 26, 2010
Appl. No.:
12/732985
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene.
Genetic Markers For Predicting Responsiveness To Combination Therapy
Genetic Markers For Predicting Responsiveness To Combination Therapy
US Patent:
2010009, Apr 15, 2010
Filed:
Jan 17, 2008
Appl. No.:
12/523522
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA
International Classification:
A61K 39/395, C12Q 1/68, C40B 40/06
US Classification:
4241581, 435 6, 506 16
Abstract:
The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy.
Genotype And Expression Analysis For Use In Predicting Outcome And Therapy Selection
Genotype And Expression Analysis For Use In Predicting Outcome And Therapy Selection
US Patent:
2011017, Jul 21, 2011
Filed:
May 14, 2009
Appl. No.:
12/992584
Inventors:
Heinz-Josef Lenz - Los Angeles CA, US
Wu Zhang - Los Angeles CA, US
Wu Zhang - Los Angeles CA, US
International Classification:
A61K 31/513, C12Q 1/68, A61P 35/00
US Classification:
514274, 435 611, 435 612, 435 61
Abstract:
The invention provides compositions and methods for determining the likelihood of successful treatment with a various treatment regimens available to gastrointestinal cancer patients. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating these patients.